Stockscreener 앱 받기
58.43
0.04%
-0.09
전일 마감가:
$58.52
열려 있는:
$58.52
하루 거래량:
596.64K
Relative Volume:
0.20
시가총액:
$26.01B
수익:
$2.44B
순이익/손실:
$1.36B
주가수익비율:
30.60
EPS:
1.9093
순현금흐름:
$574.14M
1주 성능:
+0.05%
1개월 성능:
-4.59%
6개월 성능:
+28.26%
1년 성능:
+61.42%
1일 변동 폭
$58.14
$59.02
1주일 범위
$57.82
$59.18
52주 변동 폭
$34.63
$64.38
로열티 파마 Stock (RPRX) Company Profile
명칭
Royalty Pharma Plc
전화
(212) 883-0200
주소
110 EAST 59TH STREET, NEW YORK, NY
Compare RPRX vs VRTX, REGN, MRNA, ARGX, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
RPRX
Royalty Pharma Plc
|
58.41 | 26.06B | 2.44B | 1.36B | 574.14M | 1.9093 |
VRTX
Vertex Pharmaceuticals Inc
|
513.45 | 130.53B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
795.60 | 82.77B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
184.69 | 72.88B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
950.54 | 60.30B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
362.94 | 41.64B | 5.76B | 514.49M | 1.10B | 4.4813 |
로열티 파마 Stock (RPRX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-30 | 업그레이드 | UBS | Neutral → Buy |
| 2025-09-30 | 개시 | Goldman | Buy |
| 2025-05-16 | 개시 | Morgan Stanley | Overweight |
| 2024-06-03 | 다운그레이드 | UBS | Buy → Neutral |
| 2022-06-14 | 재개 | UBS | Buy |
| 2022-05-13 | 개시 | Scotiabank | Sector Outperform |
| 2022-04-27 | 개시 | Goldman | Buy |
| 2022-04-14 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2022-04-06 | 재개 | Morgan Stanley | Overweight |
| 2021-10-29 | 업그레이드 | Citigroup | Neutral → Buy |
| 2021-07-30 | 개시 | Tigress Financial | Buy |
| 2020-11-09 | 업그레이드 | UBS | Neutral → Buy |
| 2020-07-14 | 개시 | Evercore ISI | In-line |
| 2020-07-13 | 개시 | BofA Securities | Buy |
| 2020-07-13 | 개시 | Citigroup | Neutral |
| 2020-07-13 | 개시 | Cowen | Outperform |
| 2020-07-13 | 개시 | Goldman | Neutral |
| 2020-07-13 | 개시 | JP Morgan | Neutral |
| 2020-07-13 | 개시 | Morgan Stanley | Equal-Weight |
| 2020-07-13 | 개시 | SunTrust | Buy |
| 2020-07-13 | 개시 | UBS | Neutral |
모두보기
로열티 파마 주식(RPRX)의 최신 뉴스
RPRX: Strategic AI, scalable deal models, and China expansion drive robust, diversified growth - TradingView
Royalty Pharma at Bank of America Global Healthcare Conference: growth even with policy risks - Investing.com UK
Royalty Pharma (RPRX) Stock Looks Richly Priced After Its 136% Run - Yahoo Finance
Andra AP fonden Lowers Stock Holdings in Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma (RPRX) holder plans new sale after selling 350,000 shares - Stock Titan
Royalty Pharma plc (RPRX) Stock Analysis: Exploring a 11.5% Potential Upside in the Biotech Royalty Space - DirectorsTalk Interviews
NewEdge Advisors LLC Raises Stock Position in Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma PLC $RPRX Shares Sold by Corient Private Wealth LP - MarketBeat
Could Royalty Pharma’s (NASDAQ:RPRX) Story Be Changing Fast? - Kalkine Media
Royalty Pharma PLC (NASDAQ:RPRX) Receives Consensus Recommendation of "Buy" from Analysts - MarketBeat
A $7.5 million gift will help develop new blood cancer treatments - Stock Titan
California State Teachers Retirement System Decreases Stake in Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma at Morgan Stanley conference: growth broadens beyond royalties By Investing.com - Investing.com UK
WINTON GROUP Ltd Invests $1.28 Million in Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma PLC $RPRX Shares Sold by National Pension Service - MarketBeat
Tidal Investments LLC Has $6.63 Million Holdings in Royalty Pharma PLC $RPRX - MarketBeat
(RPRX) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Wall Street Zen Upgrades Royalty Pharma (NASDAQ:RPRX) to Strong-Buy - MarketBeat
Engineers Gate Manager LP Grows Position in Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma (RPRX): Can Downside Protection Offset Pelacarsen’s Phase 3 Failure? - Yahoo Finance
Squarepoint Ops LLC Decreases Stock Holdings in Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma to present at Morgan Stanley global healthcare investor conference - Bitget
Royalty Pharma to present at upcoming investor conferences - marketscreener.com
Royalty Pharma to Present at Upcoming Investor Conferences - Moomoo
Royalty Pharma PLC $RPRX Shares Sold by C WorldWide Group Holding A S - MarketBeat
If You Invested $1000 In Royalty Pharma Stock 15 Years Ago, You Would Have This Much Today - Benzinga
TD Cowen raises Royalty Pharma stock price target on unchanged growth outlook - Investing.com Nigeria
TD Cowen raises Royalty Pharma stock price target on unchanged growth outlook By Investing.com - Investing.com South Africa
Royalty Pharma (NASDAQ:RPRX) Shares Gap DownWhat's Next? - MarketBeat
RPRX Maintained by TD Cowen -- Price Target Raised to $68.00 - GuruFocus
Royalty Pharma (RPRX) PT Raised to $68 at TD Cowen - StreetInsider
TD Cowen Issues Positive Forecast for Royalty Pharma (NASDAQ:RPRX) Stock Price - MarketBeat
Why Is Novartis Stock Falling Today?Novartis (NYSE:NVS), Ionis Pharmaceuticals (NASDAQ:IONS), Royalty - Benzinga
Royalty Pharma PLC (RPRX) Q3 2024 Earnings ReportResults, Call & Slides - TipRanks
Royalty Pharma PLC $RPRX Position Increased by TD Waterhouse Canada Inc. - MarketBeat
Royalty Pharma plc (RPRX) Stock Analysis: Navigating Growth with a 16.5% Revenue Surge - DirectorsTalk Interviews
Royalty Pharma expects modest return despite pelacarsen trial failure By Investing.com - Investing.com Australia
Royalty Pharma Updates on Novartis' HORIZON Trial Results - Intellectia AI
Royalty Pharma expects modest return despite pelacarsen trial failure - investing.com
Royalty Pharma announces update on Novartis’ Phase 3 topline results for pelacarsen - manilatimes.net
Royalty Pharma Announces Novartis HORIZON Pelacarsen Trial Results and Updates Return Outlook on Ionis Funding Agreement - Quiver Quantitative
Royalty Pharma announces update on Novartis’ Phase 3 topline results for pelacarsen - GlobeNewswire Inc.
Royalty Pharma Slides as Higher-Rate Jitters Seem to Outweigh Recent Strong Results - Quiver Quantitative
Trading the Move, Not the Narrative: (RPRX) Edition - Stock Traders Daily
Teva posts mid-stage trial win for celiac disease therapy developed with Royalty Pharma - Seeking Alpha
Royalty Pharma stock hits all-time high at 62.48 USD By Investing.com - Investing.com Australia
Public Employees Retirement System of Ohio Makes New $7.84 Million Investment in Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma (RPRX) Bets $100M On A Blood Disorder Breakthrough - Yahoo Finance
Royalty Pharma (NASDAQ:RPRX) Sets New 52-Week HighWhat's Next? - marketbeat.com
Royalty Pharma stock hits all-time high at 62.48 USD - Investing.com
RPRX Q2 2026 Earnings: EPS Misses Consensus by 22.95% as Shares Hold SteadyRevenue Guidance Update - careplusvn.com
로열티 파마 (RPRX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
로열티 파마 주식 (RPRX) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Hite Christopher | EVP & Chairman, Partnering |
Aug 18 '26 |
Sale |
59.97 |
100,000 |
5,997,250 |
370,401 |
1.21%
자본화:
|
볼륨(24시간):